Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | CFO, GC & Secretary | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-02-11 | Direct | 30,000 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 22:01 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001437749-26-004166 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-02-11 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 12:45 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 2,500 | $8.32 | $20,800.00 |
DisclosureSEC source: 0001437749-25-035653 · rdgdoc.xml · nonDerivative · entry 2 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Shares purchased in open-market transactions. F2 · price: The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $8.26 to $8.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 12:45 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 1,000 | $8.45 | $8,450.00 |
DisclosureSEC source: 0001437749-25-035653 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Shares purchased in open-market transactions. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 13:52 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 3,500 | $7.44 | $26,040.00 |
DisclosureSEC source: 0001437749-25-034639 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Shares purchased in open-market transactions. Read SEC document |
| May 14, 2025 Filed May 14, 2025 20:11 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 4,233 | $8.46 | $35,811.18 |
DisclosureSEC source: 0001437749-25-016843 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO, GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 F1 · security: Shares purchased in open-market transactions. F2 · price: Represents weighted average price of (i) 3,800 shares purchased at $8.4499 per share and (ii) 433 shares purchased at $8.5373 per share. Read SEC document |
| February 04, 2025 Filed Feb 14, 2025 23:02 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001437749-25-004074 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2025. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 20:09 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 1,000 | $18.16 | $18,160.00 |
DisclosureSEC source: 0001437749-24-027848 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · CFO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,267 F1 · security: Shares purchased in open-market transactions. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 23:45 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001437749-24-002346 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2024. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 22:51 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001437749-23-026070 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-09-15 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing September 30, 2023. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 21:17 UTC | CervoMed Inc. DFFN · Entity 7338 | ConversionSeries C Convertible Preferred Stock · Derivative | 100 | $25.00 Strike: $25.00 | $2,500.00 |
DisclosureSEC source: 0001437749-22-009233 · rdgdoc.xml · derivative · entry 2 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. F2 · derivative.exercise_price: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F2 · shares: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F2 · price: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F1 · derivative.exercise_date: As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. F1 · derivative.expiration_date: As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. F2 · derivative.underlying_shares: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F2 · balance_after: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 21:17 UTC | CervoMed Inc. DFFN · Entity 7338 | ConversionCommon Stock | 100 | $25.00 | $2,500.00 |
DisclosureSEC source: 0001437749-22-009233 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. F2 · shares: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F1 · price: As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. F2 · price: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. F2 · balance_after: All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 11:30 UTC | CervoMed Inc. DFFN · Entity 7338 | PurchaseSeries C Convertible Preferred Stock · Derivative | 5,000 | $0.50 Strike: $0.50 | $2,500.00 |
DisclosureSEC source: 0001437749-22-006872 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · security: 1. On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares. F1 · derivative.exercise_date: 1. On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares. F1 · derivative.expiration_date: 1. On March 18, 2022, the Reporting Person purchased 5,000 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Shares"), from the Issuer at a purchase price of $0.50 per Share in a private placement. The Shares have no voting rights, other than (i) each Share will be counted on an as converted basis, together with the Issuer's common stock as a single class, for purposes of determining the presence of a quorum at any meeting of the Issuer's stockholders at which a proposal related to a reverse stock split of the Issuer's common stock (a "Reverse Stock Split") will be voted upon, (ii) each Share is entitled to 80,000 votes on matters related to a Reverse Stock Split, provided that such votes must be cast For and Against each proposal on a "mirrored" basis proportional to the vote of the Issuer's common stockholders, and (iii) the right to vote as a class on certain specified matters directly related to the preferences, rights, and limitations of the Shares. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 11:04 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 305,743 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-22-001913 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,743 Underlying: Common Stock · 305,743 shares Expires 2032-01-27 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing January 31, 2022. Read SEC document |
| March 01, 2021 Filed Mar 5, 2021 00:33 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 62,522 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001437749-21-005059 · rdgdoc.xml · derivative · entry 2 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,522 Underlying: Common Stock · 62,522 shares Expires 2031-03-01 F2 · derivative.exercise_date: The amount reported reflects the maximum number of shares of common stock underlying the award that may vest based upon the achievement of specified performance metrics. The vesting of such shares is contingent upon the timely and successful achievement during the year ending December 31, 2021 of certain performance milestones related to the Issuer's planned clinical trials, with the vesting of one-third (1/3) of the total shares tied to each such milestone. If any such milestone is achieved, one-third (1/3) of the shares tied to such milestone (i.e. one-ninth (1/9) of the total shares underlying the award) will vest immediately and the remainder of the shares tied to such milestone (i.e. two-ninths (2/9) of the total shares underlying the award) will vest in 24 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 24-month period commencing January 31, 2022. In order for all shares underlying the award to vest, all three milestones mus Read SEC document |
| March 01, 2021 Filed Mar 5, 2021 00:33 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 87,684 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001437749-21-005059 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,684 Underlying: Common Stock · 87,684 shares Expires 2031-03-01 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing March 31, 2021. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 13:33 UTC | CervoMed Inc. DFFN · Entity 7338 | PurchaseCommon Stock | 5,000 | $0.63 | $3,150.00 |
DisclosureSEC source: 0001437749-20-024126 · rdgdoc.xml · nonDerivative · entry 2 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple open-market transactions at prices ranging from $0.6234 to $0.6298, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares sold at each separate price within such range. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 13:33 UTC | CervoMed Inc. DFFN · Entity 7338 | PurchaseCommon Stock | 10,000 | $0.67 | $6,700.00 |
DisclosureSEC source: 0001437749-20-024126 · rdgdoc.xml · nonDerivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple open-market transactions at prices ranging from $0.6492 to $0.6890, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 22, 2020 Filed Oct 14, 2020 23:40 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001437749-20-021143 · rdgdoc.xml · derivative · entry 1 ELDER WILLIAM ROBERT · CIK 0001828068 · GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-09-22 F1 · security: In connection with the Reporting Person's new employment with the Issuer, the Compensation Committee of the Issuer's Board of Directors approved the grant of non-qualified stock options to the Reporting Person. The grant was made as an inducement material to the Reporting Person's acceptance of employment with the Issuer, in accordance with NASDAQ Listing Rule 5635(c)(4). F2 · derivative.exercise_date: The shares underlying the options will vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 36-month period beginning October 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.